HK Stock MarketDetailed Quotes

06826 HAOHAI BIOTEC

Watchlist

37.400
-1.500-3.86%

Market Closed Apr 19 16:08 CST

6.31BMarket Cap13.74P/E (TTM)

HAOHAI BIOTEC Key Stats

Cash Flow

All

YOY

Hide blank lines

(FY)Dec 31, 2023

(Q9)Sep 30, 2023

(Q6)Jun 30, 2023

(Q3)Mar 31, 2023

(FY)Dec 31, 2022

(Q9)Sep 30, 2022

(Q6)Jun 30, 2022

(Q3)Mar 31, 2022

(FY)Dec 31, 2021

(Q9)Sep 30, 2021

Turnover

25.27%2.63B

25.23%1.98B

36.54%1.31B

29.06%611.25M

20.19%2.1B

24.14%1.58B

13.05%956.27M

23.79%473.62M

32.14%1.75B

42.89%1.27B

Operating income

25.27%2.63B

25.23%1.98B

36.54%1.31B

29.06%611.25M

20.19%2.1B

24.14%1.58B

13.05%956.27M

23.79%473.62M

32.14%1.75B

42.89%1.27B

Cost of sales

-19.02%-781.4M

----

-31.02%-379.29M

----

-33.88%-656.52M

----

-33.53%-289.48M

----

-46.82%-490.37M

----

Operating expenses

-19.02%-781.4M

-18.58%-561.89M

-31.02%-379.29M

-11.54%-174.25M

-33.88%-656.52M

-44.30%-473.85M

-33.53%-289.48M

-61.87%-156.22M

-46.82%-490.37M

-58.36%-328.37M

Gross profit

28.10%1.85B

28.07%1.42B

38.94%926.42M

37.68%437M

14.86%1.45B

17.15%1.11B

5.99%666.78M

10.95%317.4M

27.19%1.26B

38.21%946.43M

Selling expenses

-19.86%-814.51M

-25.71%-625.68M

-34.29%-420.95M

-35.33%-200.38M

-10.97%-679.53M

-19.40%-497.72M

-23.85%-313.46M

-21.25%-148.06M

-10.19%-612.34M

8.20%-416.86M

Administrative expenses

-4.20%-422.35M

3.33%-313.46M

7.36%-200.64M

-24.46%-93.65M

-41.67%-405.3M

-77.63%-324.26M

-97.08%-216.59M

-51.49%-75.24M

-31.99%-286.09M

-14.59%-182.55M

Research and development expenses

-20.81%-220.1M

-27.17%-154.15M

-32.17%-101.39M

-17.80%-53.62M

-8.71%-182.19M

-6.57%-121.22M

-4.39%-76.71M

-24.62%-45.52M

-32.51%-167.6M

-35.26%-113.75M

Profit from asset sales

----

2,281.76%518.61K

----

-100.69%-389.15

----

-132.74%-23.77K

----

842.65%56K

----

110.31%72.6K

Revaluation surplus

----

192.38%2.15M

----

--555.64K

----

---2.33M

----

-Changes in the fair value of other assets

----

192.38%2.15M

----

--555.64K

----

---2.33M

----

Impairment and provision

112.72%1.97M

78.95%-7.57M

46.67%-4.59M

-97.81%-2.38M

-587.62%-15.52M

-1,964.28%-35.94M

-193.83%-8.62M

22.15%-1.2M

132.43%3.18M

6,481.00%1.93M

-Other impairment is provision

112.72%1.97M

78.95%-7.57M

46.67%-4.59M

-97.81%-2.38M

-587.62%-15.52M

-1,964.28%-35.94M

-193.83%-8.62M

22.15%-1.2M

132.43%3.18M

6,481.00%1.93M

Operating interest expense

4.05%-7.3M

----

-42.77%-3.67M

----

-53.19%-7.6M

----

-60.55%-2.57M

----

-1.18%-4.96M

----

Special items of operating profit

54.51%116.57M

-17.33%28.09M

15.32%54.29M

158.75%10.58M

-59.98%75.45M

-44.84%33.98M

-45.31%47.08M

-77.90%4.09M

11.40%188.52M

15.40%61.59M

Operating profit

118.67%507.8M

124.27%340.65M

160.07%249.47M

96.90%95.82M

-38.96%232.22M

-47.41%151.89M

-65.01%95.93M

-47.55%48.67M

47.95%380.46M

738.93%288.82M

Financing cost

----

-17.57%47.95M

----

-26.29%15.44M

----

-13.77%58.17M

----

-4.85%20.95M

----

-16.29%67.46M

Share of profits of associates

51.50%456K

----

115.89%326K

----

223.66%301K

----

26.89%151K

----

170.99%93K

----

Share of profit from joint venture company

----

52.57%3.2M

----

--1.35M

----

--2.1M

----

Special items of earning before tax

----

235.88%746.12K

----

340.12%829.76K

----

15.30%-549.11K

----

298.33%188.53K

----

-51.99%-648.29K

Earning before tax

115.61%508.26M

85.84%389.35M

156.39%249.8M

60.58%112.1M

-38.40%235.73M

-41.09%209.51M

-64.48%97.43M

-39.15%69.81M

48.88%382.65M

210.35%355.63M

Tax

-111.46%-95.99M

-44.23%-62.38M

-76.16%-41.11M

-328.86%-27.14M

-28.36%-45.4M

-4.48%-43.25M

37.49%-23.34M

58.91%-6.33M

-15.25%-35.37M

-239.99%-41.4M

After-tax profit from continuing operations

116.61%412.27M

96.66%326.97M

181.67%208.69M

33.83%84.95M

-45.19%190.33M

-47.09%166.26M

-68.73%74.09M

-36.09%63.48M

53.43%347.28M

206.83%314.23M

Earning after tax

116.61%412.27M

96.66%326.97M

181.67%208.69M

33.83%84.95M

-45.19%190.33M

-47.09%166.26M

-68.73%74.09M

-36.09%63.48M

53.43%347.28M

206.83%314.23M

Minority profit

-139.06%-3.85M

-96.35%164.45K

12.81%3.45M

48.85%3.77M

299.17%9.86M

20.77%4.51M

-48.25%3.06M

9.18%2.54M

-32.66%-4.95M

136.48%3.73M

Profit attributable to shareholders

130.58%416.12M

102.04%326.8M

188.94%205.24M

33.21%81.18M

-48.76%180.47M

-47.91%161.75M

-69.25%71.03M

-37.17%60.94M

53.10%352.23M

175.64%310.5M

Basic earnings per share

134.62%2.44

105.38%1.91

192.68%1.2

34.29%0.47

-48.00%1.04

-47.16%0.93

-68.70%0.41

-36.36%0.35

53.85%2

179.37%1.76

Diluted earnings per share

134.62%2.44

105.38%1.91

192.68%1.2

34.29%0.47

-48.00%1.04

-47.16%0.93

-68.70%0.41

-36.36%0.35

53.85%2

179.37%1.76

Currency Unit

CNY

Accounting Standards

IAS

CAS (2007)

IAS

CAS (2007)

IAS

CAS (2007)

IAS

CAS (2007)

IAS

CAS (2007)

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young (Special General Partnership)

	(FY)Dec 31, 2023	(Q9)Sep 30, 2023	(Q6)Jun 30, 2023	(Q3)Mar 31, 2023	(FY)Dec 31, 2022	(Q9)Sep 30, 2022	(Q6)Jun 30, 2022	(Q3)Mar 31, 2022	(FY)Dec 31, 2021	(Q9)Sep 30, 2021
Turnover	25.27%2.63B	25.23%1.98B	36.54%1.31B	29.06%611.25M	20.19%2.1B	24.14%1.58B	13.05%956.27M	23.79%473.62M	32.14%1.75B	42.89%1.27B
Operating income	25.27%2.63B	25.23%1.98B	36.54%1.31B	29.06%611.25M	20.19%2.1B	24.14%1.58B	13.05%956.27M	23.79%473.62M	32.14%1.75B	42.89%1.27B
Cost of sales	-19.02%-781.4M	----	-31.02%-379.29M	----	-33.88%-656.52M	----	-33.53%-289.48M	----	-46.82%-490.37M	----
Operating expenses	-19.02%-781.4M	-18.58%-561.89M	-31.02%-379.29M	-11.54%-174.25M	-33.88%-656.52M	-44.30%-473.85M	-33.53%-289.48M	-61.87%-156.22M	-46.82%-490.37M	-58.36%-328.37M
Gross profit	28.10%1.85B	28.07%1.42B	38.94%926.42M	37.68%437M	14.86%1.45B	17.15%1.11B	5.99%666.78M	10.95%317.4M	27.19%1.26B	38.21%946.43M
Selling expenses	-19.86%-814.51M	-25.71%-625.68M	-34.29%-420.95M	-35.33%-200.38M	-10.97%-679.53M	-19.40%-497.72M	-23.85%-313.46M	-21.25%-148.06M	-10.19%-612.34M	8.20%-416.86M
Administrative expenses	-4.20%-422.35M	3.33%-313.46M	7.36%-200.64M	-24.46%-93.65M	-41.67%-405.3M	-77.63%-324.26M	-97.08%-216.59M	-51.49%-75.24M	-31.99%-286.09M	-14.59%-182.55M
Research and development expenses	-20.81%-220.1M	-27.17%-154.15M	-32.17%-101.39M	-17.80%-53.62M	-8.71%-182.19M	-6.57%-121.22M	-4.39%-76.71M	-24.62%-45.52M	-32.51%-167.6M	-35.26%-113.75M
Profit from asset sales	----	2,281.76%518.61K	----	-100.69%-389.15	----	-132.74%-23.77K	----	842.65%56K	----	110.31%72.6K
Revaluation surplus	----	192.38%2.15M	----	--555.64K	----	---2.33M	----	----	----	----
-Changes in the fair value of other assets	----	192.38%2.15M	----	--555.64K	----	---2.33M	----	----	----	----
Impairment and provision	112.72%1.97M	78.95%-7.57M	46.67%-4.59M	-97.81%-2.38M	-587.62%-15.52M	-1,964.28%-35.94M	-193.83%-8.62M	22.15%-1.2M	132.43%3.18M	6,481.00%1.93M
-Other impairment is provision	112.72%1.97M	78.95%-7.57M	46.67%-4.59M	-97.81%-2.38M	-587.62%-15.52M	-1,964.28%-35.94M	-193.83%-8.62M	22.15%-1.2M	132.43%3.18M	6,481.00%1.93M
Operating interest expense	4.05%-7.3M	----	-42.77%-3.67M	----	-53.19%-7.6M	----	-60.55%-2.57M	----	-1.18%-4.96M	----
Special items of operating profit	54.51%116.57M	-17.33%28.09M	15.32%54.29M	158.75%10.58M	-59.98%75.45M	-44.84%33.98M	-45.31%47.08M	-77.90%4.09M	11.40%188.52M	15.40%61.59M
Operating profit	118.67%507.8M	124.27%340.65M	160.07%249.47M	96.90%95.82M	-38.96%232.22M	-47.41%151.89M	-65.01%95.93M	-47.55%48.67M	47.95%380.46M	738.93%288.82M
Financing cost	----	-17.57%47.95M	----	-26.29%15.44M	----	-13.77%58.17M	----	-4.85%20.95M	----	-16.29%67.46M
Share of profits of associates	51.50%456K	----	115.89%326K	----	223.66%301K	----	26.89%151K	----	170.99%93K	----
Share of profit from joint venture company	----	----	----	----	52.57%3.2M	----	--1.35M	----	--2.1M	----
Special items of earning before tax	----	235.88%746.12K	----	340.12%829.76K	----	15.30%-549.11K	----	298.33%188.53K	----	-51.99%-648.29K
Earning before tax	115.61%508.26M	85.84%389.35M	156.39%249.8M	60.58%112.1M	-38.40%235.73M	-41.09%209.51M	-64.48%97.43M	-39.15%69.81M	48.88%382.65M	210.35%355.63M
Tax	-111.46%-95.99M	-44.23%-62.38M	-76.16%-41.11M	-328.86%-27.14M	-28.36%-45.4M	-4.48%-43.25M	37.49%-23.34M	58.91%-6.33M	-15.25%-35.37M	-239.99%-41.4M
After-tax profit from continuing operations	116.61%412.27M	96.66%326.97M	181.67%208.69M	33.83%84.95M	-45.19%190.33M	-47.09%166.26M	-68.73%74.09M	-36.09%63.48M	53.43%347.28M	206.83%314.23M
Earning after tax	116.61%412.27M	96.66%326.97M	181.67%208.69M	33.83%84.95M	-45.19%190.33M	-47.09%166.26M	-68.73%74.09M	-36.09%63.48M	53.43%347.28M	206.83%314.23M
Minority profit	-139.06%-3.85M	-96.35%164.45K	12.81%3.45M	48.85%3.77M	299.17%9.86M	20.77%4.51M	-48.25%3.06M	9.18%2.54M	-32.66%-4.95M	136.48%3.73M
Profit attributable to shareholders	130.58%416.12M	102.04%326.8M	188.94%205.24M	33.21%81.18M	-48.76%180.47M	-47.91%161.75M	-69.25%71.03M	-37.17%60.94M	53.10%352.23M	175.64%310.5M
Basic earnings per share	134.62%2.44	105.38%1.91	192.68%1.2	34.29%0.47	-48.00%1.04	-47.16%0.93	-68.70%0.41	-36.36%0.35	53.85%2	179.37%1.76
Diluted earnings per share	134.62%2.44	105.38%1.91	192.68%1.2	34.29%0.47	-48.00%1.04	-47.16%0.93	-68.70%0.41	-36.36%0.35	53.85%2	179.37%1.76
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	CAS (2007)	IAS	CAS (2007)	IAS	CAS (2007)	IAS	CAS (2007)	IAS	CAS (2007)
Audit Opinions	Unqualified Opinion	--	--	--	Unqualified Opinion	--	--	--	Unqualified Opinion	--
Auditor	Ernst & Young (Special General Partnership)	--	--	--	Ernst & Young (Special General Partnership)	--	--	--	Ernst & Young (Special General Partnership)	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

06826 HAOHAI BIOTEC

HAOHAI BIOTEC Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Analysis

Analyst Rating

Price Target